超碰123,无遮挡激情视频国产在线观看,9色在线视频

FDA Approved Summay - November 2024 FDA FDA Drug Approvals November 2024 FDA approvals include treatments for rare diseases, cancers, diabetes, and more. Highlights include Applied Therapeutics' Govorestat for galactosemia and UCB's Bimzelx for hidradenitis suppurativa. Explore key updates on new therapies.
FDA Accelerated Approval Market Withdrawal FDA Explore the FDA’s accelerated approval pathway and its impact on the market, highlighting five drugs—Oxbryta, Aduhelm, Exkivity, Ukoniq, and Zydelig—that were withdrawn after initial approval. Understand the challenges and risks associated with accelerated drug approvals.
FDA Approved Summay - October 2024 FDA FDA Drug Approvals Explore the latest FDA drug approvals for October 2024, including treatments for Alzheimer's, cancer, Parkinson’s, and rare diseases, along with expanded indications for leukemia and pediatric care.
FDA Guidelines on Control of Nitrosamine Impurities FDA Stay informed FDA's updated guidelines on controlling nitrosamine impurities in pharmaceuticals. In september 2024, these guidelines provide essential strategies for manufacturers to detect, prevent, and manage nitrosamine risks, ensuring safer drug production and compliance with health regulations.
Will the Biosecure act passed during lame duck session? Biosecure Act FDA WuXi AppTec Get insights into the anticipated passage of the Biosecure Act during Congress's lame-duck session. With bipartisan support and strategic amendments, experts predict a high likelihood of success.
FDA Approved Summay - September 2024 FDA FDA Drug Approvals latest FDA drug approvals from September 2024, featuring groundbreaking treatments like Fresenius Kabi's Otulfi for inflammatory diseases, Dupixent for COPD, and innovative therapies for rare conditions.
Studying FDA Major Deficiencies to Support the Export or Successful Registration of Domestic Medicines FDA Learn how studying FDA major deficiencies can enhance drug research and registration success in China. Explores FDA standards, common deficiencies, and solutions to improve formulations, compliance, and export potential for Chinese pharmaceutical products in global markets.
EMA Takes Action on Metamizole-Induced Risks EMA The EMA has issued new recommendations to mitigate agranulocytosis risks associated with metamizole, urging increased awareness among healthcare providers and patients. Symptoms include fever and sore throat; immediate medical attention is crucial.
EU Imposes New Restrictions on PFAS Chemicals EU ECHA The European Commission has adopted new restrictions on PFHxA and related PFAS under the REACH Regulation, targeting consumer textiles, food packaging, cosmetics. Effective 20 days post-publication.
NIH Trial Confirms Bone Marrow Cancer Drug Efficacy NIH A recent NIH-supported trial confirms the efficacy of pomalidomide in treating hereditary hemorrhagic telangiectasia (HHT), a rare blood disorder.

< Pre 1 2 345 6 Next >

News Archives

All Categories

Industry News Agricultural News Industrial News Cosmetic News Exhibition News Food News Science News Pharmaceutical News

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a

Chemical Policy

HOT Topics